Director Koo Jakap made one open market purchase of Apimeds Pharmaceuticals US, Inc. ($APUS) shares in the last year, totaling $56,715, with the most recent on May 12, 2025. This ranks 2,862nd among 4,983 insiders, below the average of 1.5 million per buyer and 3.3 transactions. No open market sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov. 11, 2025 | Apimeds Pharmaceuticals US, Inc. | $APUS | Koo Jakap | Director | A | Stock Option (right to buy) | 10000 | $0.00 | 10,000.0000 | 12,575,983 | 9999.99% | 0.08% |
| Oct. 15, 2025 | Apimeds Pharmaceuticals US, Inc. | $APUS | Koo Jakap | Director | A | Stock Option (right to buy) | 3000 | $0.00 | 3,000.0000 | 12,575,983 | 9999.99% | 0.02% |
| May 16, 2025 | Apimeds Pharmaceuticals US, Inc. | $APUS | Koo Jakap | Director | A | Stock Option (right to buy) | 5780 | $0.00 | 5,780.0000 | 7,903,850 | 9999.99% | 0.07% |
| May 12, 2025 | Apimeds Pharmaceuticals US, Inc. | $APUS | Koo Jakap | Director | P | Common Stock, par value $0.01 per share | 28500 | $1.99 | 643,885.0000 | 7,903,850 | 4.63% | 0.36% |